二甲双胍联合罗格列酮治疗Ⅱ型糖尿病疗效与安全评价

Evaluation on the Efficacy and Safety of metformin combined with Rosiglitazone in treatment of type II diabetes

目的探讨二甲双胍联合罗格列酮治疗Ⅱ型糖尿病的疗效和联合用药的安全性。方法选择经Ⅱ型糖尿病患者120例,按入院先后顺序随机分为A、B、C组,每组40例。A组接受罗格列酮治疗,B组接受盐酸二甲双胍治疗,C组接受罗格列酮+盐酸二甲双胍治疗,疗程均为12周,并对3组的疗效进行比较。结果 3组的FBG、2hBG、HbAlc、FINS、TC及TG均较治疗前明显下降(P<0.05)。C组的ISI升高较其它两组明显,FBG、2hBG、HbAlc的下降较其它两组明显;FINS下降较B组明显(P<0.05)。C组不良反应却较其它两组明显减少(P<0.05)。结论二甲双胍联合罗格列酮治疗Ⅱ型糖尿病,疗效好而不良反应轻,优于两种药单用,可作为临床的用药选择。

Objective To evaluate the efficacy and the safety of metformin combined with rosiglitazone in treatment of type Ⅱ diabetes. Methods 120 patients with type Ⅱ diabetes were included in the study. According to admission, all cases were randomly divided into A, B, C groups （n = 40）. Group A received rosiglitazone therapy; group B received metformin hydrochloride; group C received rosiglitazone and metformin hydrochloride therapy, the therapy course lasted for 12 weeks. The clinical efficacy of the 3 groups were compared. Results Three groups of FBG, 2hBG, HbAlc, FINS, TC and TG significantly decreased compared to those before treatment （P〈0. 05）. The ISI in Group C was significantly higher than the other two groups; FBG, 2hBG, and HbAle decreased significantly compared to the other two groups, FINS significantly decreased in group B （P〈0.05）. The adverse reactions in group C was higher than the other two groups （P〈0. 05）. Conclusion Metformin combined with rosiglitazone in treatment of type Ⅱdiabetes has a better efficacy and lower adverse reactions than the two drugs alone, it can be used as an ideal choice for medication.